Thera-SAbDab

NECITUMUMAB

>   Structural Summary
TherapeuticNecitumumab
TargetEGFR
Heavy ChainQVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSS
Light ChainEIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIK
100% seqID Fv Structure6b3s%3AJK%3ACD%3AHL%3AFG%2F3b2u%3AWX%3AQR%3ATU%3AJK%3ACD%3ANO%3AFG%3AHL%2F3b2v%3AHL [Fvs: ]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (August '23)Approved
Estimated Status (August '23)Active
Recorded Developmental Technologyna
INN Year Proposed2008
INN Year Recommended2009
Companies InvolvedImClone Systems%3BEli Lilly
Conditions ApprovedNon-small cell lung cancer
Conditions ActiveSolid tumours
Conditions DiscontinuedColorectal cancer
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy